Biogen (BUE:BIIB) 5-Year EBITDA Growth Rate

: -5.30% (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's EBITDA per Share for the three months ended in Mar. 2023 was ARS834.15.

During the past 12 months, Biogen's average EBITDA Per Share Growth Rate was 57.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -10.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -5.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biogen was 161.50% per year. The lowest was -18.60% per year. And the median was 22.65% per year.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen 5-Year EBITDA Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Biogen's 5-Year EBITDA Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 5-Year EBITDA Growth Rate's extreme value range as defined by GuruFocus.

Biogen 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Biogen (BUE:BIIB) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Biogen 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Biogen's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.